PRCT
NASDAQ HealthcarePROCEPT BioRobotics Corporation
$19.20
-$1.10 (-5.42%)
Live quote
52w: $16.67 – $38.11
Loading chart…
P/E Ratio—
P/B Ratio3.42
EV/EBITDA—
Debt/Equity—
ROE-28.10%
ROIC—
Revenue Growth37.22%
Gross Margin63.70%
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Own PRCT? Track it here.
Create a free account to add PRCT to a portfolio and watch your P/L update in real time.
Custom screens, valuation models and backtesting are coming to Pro.